Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.4 USD | -6.40% | -0.70% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA | - | - | - | -8.842 |
EBIT 1 | -1.169 | -1.578 | -4.467 | -8.889 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.169 | -1.582 | -5.121 | -16.48 |
Net income 1 | -1.169 | -1.582 | -5.121 | -16.48 |
Net margin | - | - | - | - |
EPS 2 | -0.1336 | -0.1808 | -0.1814 | -0.6751 |
Free Cash Flow | - | - | -1.688 | 3.832 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 10/02/23 | 10/02/23 | 18/05/23 | 29/02/24 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt | - | 1.12 | 5.26 | - |
Net Cash position | - | - | - | 7.28 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | -1.69 | 3.83 |
ROE (net income / shareholders' equity) | - | 245% | 194% | 1,202% |
ROA (Net income/ Total Assets) | - | - | -106% | -66.8% |
Assets 1 | - | - | 4.853 | 24.7 |
Book Value Per Share 2 | - | -0.0300 | -0.1400 | 0.0400 |
Cash Flow per Share | - | 0.0100 | 0.0800 | 0.3200 |
Capex | - | - | - | 0.5 |
Capex / Sales | - | - | - | - |
Announcement Date | 10/02/23 | 10/02/23 | 18/05/23 | 29/02/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 370M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.96% | 22.48B | |
-9.58% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- FBLG Stock
- Financials FibroBiologics, Inc.